We describe results of testing blood donors in London, UK, for severe acute respiratory disease coronavirus 2 (SARS-CoV-2) IgG before and after lockdown measures. Anonymized samples from donors 17–69 years of age were tested using 3 assays: Euroimmun IgG, Abbott IgG, and an immunoglobulin receptor-binding domain assay developed by Public Health England. Seroprevalence increased from 3.0% prelockdown (week 13, beginning March 23, 2020) to 10.4% during lockdown (weeks 15–16) and 12.3% postlockdown (week 18) by the Abbott assay. Estimates were 2.9% prelockdown, 9.9% during lockdown, and 13.0% postlockdown by the Euroimmun assay and 3.5% prelockdown, 11.8% during lockdown, and 14.1% postlockdown by the receptor-binding domain assay. By early Ma...
Background and Objectives: During the pandemic of COVID-19, additional blood donor eligibility crit...
Introduction: An estimated 1.5 million cases were reported in Pakistan until 23 March, 2022. However...
Background: A large proportion of SARS-CoV-2-infected individuals does not develop severe symptoms. ...
We describe results of testing blood donors in London, UK, for severe acute respiratory disease coro...
We describe results of testing blood donors in London, UK, for severe acute respiratory disease coro...
Background. The progression and geographical distribution of SARS coronavirus 2 (SARS-CoV-2) infecti...
Abstract Background Epidemic projections and public health policies addressing Coronavirus disease (...
Projections of the stage of the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemi...
We investigated the dynamics of seroconversion in severe acute respiratory syndrome coronavirus 2 (S...
BackgroundThe Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P) Epidemiolog...
Rapidly identifying and isolating people with acute SARS-CoV-2 infection has been a core strategy to...
Rapidly identifying and isolating people with acute SARS-CoV-2 infection has been a core strategy to...
International audienceWe conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in ...
Cross-sectional studies of the prevalence of anti-SARS-CoV-2 in representative groups are routinely ...
The early transmission dynamics of SARS-CoV-2 in the UK are unknown but their investigation is criti...
Background and Objectives: During the pandemic of COVID-19, additional blood donor eligibility crit...
Introduction: An estimated 1.5 million cases were reported in Pakistan until 23 March, 2022. However...
Background: A large proportion of SARS-CoV-2-infected individuals does not develop severe symptoms. ...
We describe results of testing blood donors in London, UK, for severe acute respiratory disease coro...
We describe results of testing blood donors in London, UK, for severe acute respiratory disease coro...
Background. The progression and geographical distribution of SARS coronavirus 2 (SARS-CoV-2) infecti...
Abstract Background Epidemic projections and public health policies addressing Coronavirus disease (...
Projections of the stage of the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemi...
We investigated the dynamics of seroconversion in severe acute respiratory syndrome coronavirus 2 (S...
BackgroundThe Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P) Epidemiolog...
Rapidly identifying and isolating people with acute SARS-CoV-2 infection has been a core strategy to...
Rapidly identifying and isolating people with acute SARS-CoV-2 infection has been a core strategy to...
International audienceWe conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in ...
Cross-sectional studies of the prevalence of anti-SARS-CoV-2 in representative groups are routinely ...
The early transmission dynamics of SARS-CoV-2 in the UK are unknown but their investigation is criti...
Background and Objectives: During the pandemic of COVID-19, additional blood donor eligibility crit...
Introduction: An estimated 1.5 million cases were reported in Pakistan until 23 March, 2022. However...
Background: A large proportion of SARS-CoV-2-infected individuals does not develop severe symptoms. ...